Table 1.
Selected Characteristics of Enrolled Subjects
| Exposed to PI-based regimens (n=46)a | Exposed to NNRTI-based regimens (n=52)a | p value | |
|---|---|---|---|
| Sex (M/F) | 46/0 | 52/0 | |
| Age (mean±SD) | 33.7±8.8 | 35.1±7.6 | 0.4 |
| Baseline CD4+ cell count (/μl) (mean±SD) | 245.1±90.7 | 256.8±85.6 | 0.513 |
| Baseline plasma HIV-1 DNA (×103 copies/ml) (mean±SD) | 28±19 | 31±17 | 0.411 |
| CD4+ cell count at enrollment (/μl) (mean±SD) | 284.5±86.7 | 267.8±78.5 | 0.319 |
| Plasma HIV-1 DNA at enrollment (×103 copies/ml) (mean±SD) | 19±12 | 16±13 | 0.24 |
| Duration of exposure to antiretroviral drugs (weeks) (mean±SD) | 74±21 | 68±23 | 0.183 |
a
A total of 18 subjects were exposed to both PI-based and NNRTI-based regimens.
PI, protease inhibitors; NNRTI, nonnucleoside analogue reverse transcriptase inhibitors.